Technical Analysis for TRVI - Trevi Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 7.21 -2.57% -0.19
TRVI closed down 2.57 percent on Monday, July 15, 2019, on 4 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical TRVI trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -2.57%
Shooting Star Candlestick Bearish -2.57%
Stochastic Buy Signal Bullish -2.57%
Wide Bands Range Expansion -2.57%
Oversold Stochastic Weakness -2.57%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%

Older signals for TRVI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
Biopharmaceutical Organ Systems Chemical Compounds Organic Compounds Analgesics Morphinans Ethers Idiopathic Pulmonary Fibrosis Phenols Parkinson’s Disease Levodopa Induced Dyskinesia Prurigo
Is TRVI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.62
52 Week Low 5.69
Average Volume 69,151
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 7.8215
10-Day Moving Average 7.381
Average True Range 0.7463
ADX 21.13
+DI 14.1424
-DI 19.2382
Chandelier Exit (Long, 3 ATRs ) 7.7811
Chandelier Exit (Short, 3 ATRs ) 7.9289
Upper Bollinger Band 9.0639
Lower Bollinger Band 6.5791
Percent B (%b) 0.25
BandWidth 31.768842
MACD Line -0.335
MACD Signal Line -0.3064
MACD Histogram -0.0287
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.86
Resistance 3 (R3) 7.91 7.76 7.75
Resistance 2 (R2) 7.76 7.59 7.73 7.71
Resistance 1 (R1) 7.48 7.49 7.41 7.43 7.68
Pivot Point 7.33 7.33 7.29 7.30 7.33
Support 1 (S1) 7.05 7.16 6.98 7.00 6.74
Support 2 (S2) 6.90 7.06 6.87 6.71
Support 3 (S3) 6.62 6.90 6.67
Support 4 (S4) 6.57